Laura Shawver
CIK: 0001551891
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
ARS Pharmaceuticals, Inc.
Discretionary Trading P&L
Holdings
Transaction History (23 total)
- Jun 24, 2026SPRY
ARS Pharmaceuticals, Inc.
Award(A)DirectStock Option (right to buy)
30K shares- - Jun 25, 2025SPRY
ARS Pharmaceuticals, Inc.
Award(A)DirectStock Option (right to buy)
30K shares- - Apr 7, 2025SPRY
ARS Pharmaceuticals, Inc.
Sale(S)Direct50K shares at avg. $12.30$615K - Apr 7, 2025SPRY
ARS Pharmaceuticals, Inc.
Exercise(M)Direct22.5K shares at avg. $4.85$109K - Apr 7, 2025SPRY
ARS Pharmaceuticals, Inc.
Exercise(M)Direct27.5K shares at avg. $4.85$133K - Mar 6, 2025SPRY
ARS Pharmaceuticals, Inc.
Exercise(M)Direct49.6K shares at avg. $4.85$241K - Mar 6, 2025SPRY
ARS Pharmaceuticals, Inc.
Sale(S)Direct49.6K shares at avg. $11.21$556K - Mar 5, 2025SPRY
ARS Pharmaceuticals, Inc.
Exercise(M)Direct400 shares at avg. $4.85$2K - Mar 5, 2025SPRY
ARS Pharmaceuticals, Inc.
Sale(S)Direct400 shares at avg. $11.00$4K - Feb 3, 2025SPRY
ARS Pharmaceuticals, Inc.
Sale(S)Direct50K shares at avg. $12.31$616K - Feb 3, 2025SPRY
ARS Pharmaceuticals, Inc.
Exercise(M)Direct9.1K shares at avg. $3.15$29K - Feb 3, 2025SPRY
ARS Pharmaceuticals, Inc.
Exercise(M)Direct40.9K shares at avg. $4.85$199K - Jan 6, 2025SPRY
ARS Pharmaceuticals, Inc.
Sale(S)Direct50K shares at avg. $11.10$555K - Jan 6, 2025SPRY
ARS Pharmaceuticals, Inc.
Exercise(M)Direct50K shares at avg. $3.15$158K - Dec 4, 2024SPRY
ARS Pharmaceuticals, Inc.
Exercise(M)Direct14.8K shares at avg. $3.15$47K - Dec 4, 2024SPRY
ARS Pharmaceuticals, Inc.
Sale(S)Direct14.8K shares at avg. $13.75$203K - Dec 3, 2024SPRY
ARS Pharmaceuticals, Inc.
Exercise(M)Direct62.4K shares at avg. $3.15$196K - Dec 3, 2024SPRY
ARS Pharmaceuticals, Inc.
Exercise(M)Direct25.6K shares at avg. $1.27$33K - Dec 3, 2024SPRY
ARS Pharmaceuticals, Inc.
Sale(S)Direct88K shares at avg. $13.26$1.2M - Dec 2, 2024SPRY
ARS Pharmaceuticals, Inc.
Exercise(M)Direct29.6K shares at avg. $1.27$38K - Dec 2, 2024SPRY
ARS Pharmaceuticals, Inc.
Sale(S)Direct901 shares at avg. $14.34$13K - Dec 2, 2024SPRY
ARS Pharmaceuticals, Inc.
Exercise(M)Direct67.6K shares at avg. $1.27$86K - Dec 2, 2024SPRY
ARS Pharmaceuticals, Inc.
Sale(S)Direct96.3K shares at avg. $13.55$1.3M
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 24, 2026 | SPRY ARS Pharmaceuticals, Inc. | Award(A) Stock Option (right to buy) | 30,000 | - | - | Direct |
| Jun 25, 2025 | SPRY ARS Pharmaceuticals, Inc. | Award(A) Stock Option (right to buy) | 30,000 | - | - | Direct |
| Apr 7, 2025 | SPRY ARS Pharmaceuticals, Inc. | Sale(S) | 50,002 | $12.30 | $615,075 | Direct |
| Apr 7, 2025 | SPRY ARS Pharmaceuticals, Inc. | Exercise(M) | 22,509 | $4.85 | $109,169 | Direct |
| Apr 7, 2025 | SPRY ARS Pharmaceuticals, Inc. | Exercise(M) | 27,493 | $4.85 | $133,341 | Direct |
| Mar 6, 2025 | SPRY ARS Pharmaceuticals, Inc. | Exercise(M) | 49,600 | $4.85 | $240,560 | Direct |
| Mar 6, 2025 | SPRY ARS Pharmaceuticals, Inc. | Sale(S) | 49,600 | $11.21 | $556,046 | Direct |
| Mar 5, 2025 | SPRY ARS Pharmaceuticals, Inc. | Exercise(M) | 400 | $4.85 | $1,940 | Direct |
| Mar 5, 2025 | SPRY ARS Pharmaceuticals, Inc. | Sale(S) | 400 | $11.00 | $4,400 | Direct |
| Feb 3, 2025 | SPRY ARS Pharmaceuticals, Inc. | Sale(S) | 50,000 | $12.31 | $615,565 | Direct |
| Feb 3, 2025 | SPRY ARS Pharmaceuticals, Inc. | Exercise(M) | 9,064 | $3.15 | $28,552 | Direct |
| Feb 3, 2025 | SPRY ARS Pharmaceuticals, Inc. | Exercise(M) | 40,936 | $4.85 | $198,540 | Direct |
| Jan 6, 2025 | SPRY ARS Pharmaceuticals, Inc. | Sale(S) | 50,000 | $11.10 | $555,065 | Direct |
| Jan 6, 2025 | SPRY ARS Pharmaceuticals, Inc. | Exercise(M) | 50,000 | $3.15 | $157,500 | Direct |
| Dec 4, 2024 | SPRY ARS Pharmaceuticals, Inc. | Exercise(M) | 14,772 | $3.15 | $46,532 | Direct |
| Dec 4, 2024 | SPRY ARS Pharmaceuticals, Inc. | Sale(S) | 14,772 | $13.75 | $203,109 | Direct |
| Dec 3, 2024 | SPRY ARS Pharmaceuticals, Inc. | Exercise(M) | 62,378 | $3.15 | $196,491 | Direct |
| Dec 3, 2024 | SPRY ARS Pharmaceuticals, Inc. | Exercise(M) | 25,606 | $1.27 | $32,520 | Direct |
| Dec 3, 2024 | SPRY ARS Pharmaceuticals, Inc. | Sale(S) | 87,984 | $13.26 | $1,166,897 | Direct |
| Dec 2, 2024 | SPRY ARS Pharmaceuticals, Inc. | Exercise(M) | 29,628 | $1.27 | $37,628 | Direct |
| Dec 2, 2024 | SPRY ARS Pharmaceuticals, Inc. | Sale(S) | 901 | $14.34 | $12,922 | Direct |
| Dec 2, 2024 | SPRY ARS Pharmaceuticals, Inc. | Exercise(M) | 67,616 | $1.27 | $85,872 | Direct |
| Dec 2, 2024 | SPRY ARS Pharmaceuticals, Inc. | Sale(S) | 96,343 | $13.55 | $1,305,823 | Direct |
1-23 of 23 transactions
About Shawver Laura
Shawver Laura (SEC CIK 0001551891) files insider reports with the SEC as Director of ARS Pharmaceuticals, Inc. (SPRY).
Signal8 holds 7 ownership filings by Shawver Laura, all Form 4s, filed between Dec 4, 2024 and Jun 26, 2026. Those filings report 23 transactions, from Dec 2, 2024 to Jun 24, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Shawver Laura's filings is in SAN DIEGO, CA.
Recent filings by Shawver Laura
- Jun 24, 2026: Grant or award of SPRY derivative securities (Form 4, code A).
- Jun 25, 2025: Grant or award of SPRY derivative securities (Form 4, code A).
- Apr 7, 2025: Open-market sale of SPRY shares (Form 4, code S).
- Apr 7, 2025: Option exercises of SPRY shares (2 lines, Form 4, code M).
- Mar 6, 2025: Option exercise of SPRY shares (Form 4, code M).
Other insiders filing for ARS Pharmaceuticals, Inc. (SPRY)
- Casale Donn, President and CEO
- Smith Margaret Ekins, Chief Commercial Officer
- RA CAPITAL MANAGEMENT, L.P., Director
- Dadoo Rajeev, Director
- Shah Pratik, Director
- Kelly Michael, Director